ES2109189A1 - Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas. - Google Patents

Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.

Info

Publication number
ES2109189A1
ES2109189A1 ES9600620A ES9600620A ES2109189A1 ES 2109189 A1 ES2109189 A1 ES 2109189A1 ES 9600620 A ES9600620 A ES 9600620A ES 9600620 A ES9600620 A ES 9600620A ES 2109189 A1 ES2109189 A1 ES 2109189A1
Authority
ES
Spain
Prior art keywords
genome
defective viral
virus
recombinant
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES9600620A
Other languages
English (en)
Other versions
ES2109189B1 (es
Inventor
Sanchez Luis Enjuanes
Parmesan Ander Izeta
Picazo Cristian Smerdou
Zunzunegui Ana Mendez
Jareno Maria Luisa Ballesteros
Sanchez Carlos M Sanchez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Farma SA
Original Assignee
Cyanamid Iberica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES9600620A priority Critical patent/ES2109189B1/es
Application filed by Cyanamid Iberica SA filed Critical Cyanamid Iberica SA
Priority to AU19277/97A priority patent/AU729044B2/en
Priority to EP19970907111 priority patent/EP1008652A1/en
Priority to PCT/ES1997/000059 priority patent/WO1997034008A1/es
Priority to RU98118555A priority patent/RU2199584C2/ru
Priority to PL97328791A priority patent/PL188546B1/pl
Priority to JP53230497A priority patent/JP3769300B2/ja
Priority to US09/155,003 priority patent/US7041300B1/en
Priority to HU0000356A priority patent/HUP0000356A3/hu
Priority to CA 2248978 priority patent/CA2248978A1/en
Priority to EP20060013756 priority patent/EP1741789A1/en
Priority to BR9708061A priority patent/BR9708061A/pt
Priority to CNB971946140A priority patent/CN1318596C/zh
Priority to KR10-1998-0707192A priority patent/KR100360327B1/ko
Publication of ES2109189A1 publication Critical patent/ES2109189A1/es
Application granted granted Critical
Publication of ES2109189B1 publication Critical patent/ES2109189B1/es
Priority to US10/444,059 priority patent/US20040052775A1/en
Priority to US11/503,214 priority patent/US20070048862A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A61K39/225—Porcine transmissible gastroenteritis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20064—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LOS VECTORES COMPRENDEN UN GENOMA VIRAL DEFECTIVO RECOMBINANTE QUE EXPRESA AL MENOS UN ANTIGENO ADECUADO PARA LA INDUCCION DE RESPUESTAS INMUNES SISTEMICAS Y SECRETORAS. EL GENOMA VIRAL DEFECTIVO COMPRENDE EL GENOMA DE UN VIRUS PARENTAL QUE TIENE LAS SEÑALES DE RECONOCIMIENTO DE LA REPLICASA VIRAL LOCALIZADAS EN LOS EXTREMOS (3'') Y (5''), QUE COMPRENDE ADEMAS DELACIONES INTERNAS, Y EN DONDE DICHO GENOMA VIRAL DEFECTIVO DEPENDE DE UN VIRUS COMPLEMENTADOR PARA SU REPLICACION. ESTOS VECTORES SON ADECUADOS PARA FORMAR UN SISTEMA RECOMBINANTE QUE COMPRENDE (A) DICHO VECTOR DE EXPRESION, Y (B) UN VIRUS COMPLEMENTADOR QUE PROPORCIONA LAS PROTEINAS FUNCIONALES Y ESTRUCTURALES PARA LA REPLICACION Y ENCAPSIDACION DEL GENOMA DEFECTIVO. ESTE SISTEMA ES ADECUADO PARA LA ELABORACION DE VACUNAS MONO Y POLIVALENTES FRENTE AGENTES INFECCIOSOS DE DISTINTAS ESPECIES ANIMALES, ESPECIALMENTE CERDOS, PERROS Y GATOS.
ES9600620A 1996-03-14 1996-03-14 Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas. Expired - Fee Related ES2109189B1 (es)

Priority Applications (16)

Application Number Priority Date Filing Date Title
ES9600620A ES2109189B1 (es) 1996-03-14 1996-03-14 Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
EP20060013756 EP1741789A1 (en) 1996-03-14 1997-03-12 Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
PCT/ES1997/000059 WO1997034008A1 (es) 1996-03-14 1997-03-12 Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas
RU98118555A RU2199584C2 (ru) 1996-03-14 1997-03-12 Вектор (варианты), основанный на рекомбинантном дефектном вирусном геноме, и его применение для создания препаратов вакцин
PL97328791A PL188546B1 (pl) 1996-03-14 1997-03-12 Wektor ekspresyjny antygenów lub przeciwciał, rekombinacyjny układ ekspresyjny i szczepionka do ochrony zwierząt
JP53230497A JP3769300B2 (ja) 1996-03-14 1997-03-12 組換え欠陥ウイルスゲノムに基づくベクター及びワクチン製剤におけるそれらの使用
US09/155,003 US7041300B1 (en) 1996-03-14 1997-03-12 Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
HU0000356A HUP0000356A3 (en) 1996-03-14 1997-03-12 Vectors based on recombinant defective viral genomes,and their use in the formulation of vaccines
AU19277/97A AU729044B2 (en) 1996-03-14 1997-03-12 Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
EP19970907111 EP1008652A1 (en) 1996-03-14 1997-03-12 Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
BR9708061A BR9708061A (pt) 1996-03-14 1997-03-12 Vetores baseados em genomas virais defeituosos recombinantes, e seu uso na formação de vacinas.
CNB971946140A CN1318596C (zh) 1996-03-14 1997-03-12 基于重组缺损病毒基因组的载体及其在疫苗制剂中的应用
KR10-1998-0707192A KR100360327B1 (ko) 1996-03-14 1997-03-12 재조합결함성바이러스게놈계벡터및이들벡터를백신의제형화에사용하는방법
CA 2248978 CA2248978A1 (en) 1996-03-14 1997-03-12 Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
US10/444,059 US20040052775A1 (en) 1996-03-14 2003-05-23 Vectors based on recombinant defective viral genomes and their use in the formulation of vaccines
US11/503,214 US20070048862A1 (en) 1996-03-14 2006-08-14 Vectors based on recombinant defective viral genomes and their use in the formulation of vaccines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9600620A ES2109189B1 (es) 1996-03-14 1996-03-14 Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.

Publications (2)

Publication Number Publication Date
ES2109189A1 true ES2109189A1 (es) 1998-01-01
ES2109189B1 ES2109189B1 (es) 1998-05-16

Family

ID=8294176

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9600620A Expired - Fee Related ES2109189B1 (es) 1996-03-14 1996-03-14 Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.

Country Status (13)

Country Link
US (3) US7041300B1 (es)
EP (2) EP1008652A1 (es)
JP (1) JP3769300B2 (es)
KR (1) KR100360327B1 (es)
CN (1) CN1318596C (es)
AU (1) AU729044B2 (es)
BR (1) BR9708061A (es)
CA (1) CA2248978A1 (es)
ES (1) ES2109189B1 (es)
HU (1) HUP0000356A3 (es)
PL (1) PL188546B1 (es)
RU (1) RU2199584C2 (es)
WO (1) WO1997034008A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062424A1 (es) * 2002-01-24 2003-07-31 Consejo Superior De Investigaciones Científicas Secuencia de acido nucleico que comprende la señal de encapsidación del rna de un coronavirus del grupo 1 y sus aplicaciones
US7368557B2 (en) 1999-12-03 2008-05-06 Consejo Superior De Investigationes Cientificas Polynucleotides encoding porcine transmissible gastroenteritis virus

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL210451B1 (pl) * 1999-06-10 2012-01-31 Merial Sas Szczepionka DNA przeciwko wirusowi nosówki psów (CDV)
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
SG149684A1 (en) 2001-01-19 2009-02-27 Vironovative Bv A virus causing respiratory tract illness in susceptible animals
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
KR101076102B1 (ko) 2002-02-21 2011-10-21 비로노바티브 비.브이. 메타뉴모바이러스에서 유래한 이종성 항원을 포함하는재조합 파라인플루엔자 바이러스 발현 시스템 및 백신
ES2233145B1 (es) * 2002-11-20 2006-07-16 Laboratorios Hipra, S.A. Vacuna viva atenuada contra la pleuroneumonia porcina.
CA2523319A1 (en) 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
EP1789566A1 (en) * 2004-09-03 2007-05-30 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
EP1650308A1 (en) * 2004-09-03 2006-04-26 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US20090304738A1 (en) * 2005-06-16 2009-12-10 Moran Thomas M Methods for Enhancing Immune Responses
EP1792996A1 (en) 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
BRPI0800485B8 (pt) * 2008-01-17 2021-05-25 Univ Minas Gerais vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
BRPI0822947B1 (pt) * 2008-11-19 2018-09-18 Laboratorio Avi Mex S A De Cv vacina recombinante.
CN104262488B (zh) * 2014-09-24 2017-07-28 普莱柯生物工程股份有限公司 一种融合蛋白及其疫苗组合物的制备与应用
US20230174953A1 (en) * 2020-03-27 2023-06-08 Institut Pasteur Defective interfering viral genomes
EP4136218A1 (en) * 2020-04-12 2023-02-22 Novoscope IP Limited Particles, dna & rna
WO2022031683A1 (en) * 2020-08-03 2022-02-10 The Penn State Research Foundation Synthetic defective interfering coronaviruses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003552A1 (en) * 1989-08-28 1991-03-21 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression systems and vaccines
WO1994017098A1 (es) * 1993-01-23 1994-08-04 Inmunologia Y Genetica Aplicada, S.A. Peptidos y vacunas sinteticos contra parvovirus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2031122C1 (ru) * 1992-09-07 1995-03-20 Владимир Иванович Грабко Способ встраивания гетерологичной днк в геном аденовируса celo и рекомбинантный аденовирусный вектор celo/рuc19

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003552A1 (en) * 1989-08-28 1991-03-21 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression systems and vaccines
WO1994017098A1 (es) * 1993-01-23 1994-08-04 Inmunologia Y Genetica Aplicada, S.A. Peptidos y vacunas sinteticos contra parvovirus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHING-LEN LIAO et al. "Coronavirus Defective-Interfering RNA as an Expression Vector: The Generation of a Pseudorecombinant Mouse Hepatitis Virus Expressing Hemagglutinin-Esterase" Virology. 1995. Vol. 208, paginas 319-327 *
MENDEZ, ANA et al. "Structure and encapsidation of transmissible gastroenteritis coronavirus (TGEV) defective interfering genomes" CORONA AND RELATED VIRUSES 1995. Vol. 380, pßginas 583-588 *
RUEY-YI CHANG et al. "A cis-Acting Function for The Coronavirus Leader in Defective Interfering RNA Replication" JOURNAL OF VIROLOGY. 1994. Vol. 68, n‘ 12, pßginas 8223-8231 *
VAN DER MOST, ROBBERT G. et al. "A Domain at the 3' End of The Polymerase Gene Is Essential for Encapsidation of Coronavirus Defective Interfering RNAs" JOURNAL OF VIROLOGY. 1991. Vol. 65 (6), pßginas 3219-3226 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368557B2 (en) 1999-12-03 2008-05-06 Consejo Superior De Investigationes Cientificas Polynucleotides encoding porcine transmissible gastroenteritis virus
WO2003062424A1 (es) * 2002-01-24 2003-07-31 Consejo Superior De Investigaciones Científicas Secuencia de acido nucleico que comprende la señal de encapsidación del rna de un coronavirus del grupo 1 y sus aplicaciones
ES2208051A1 (es) * 2002-01-24 2004-06-01 Consejo Sup. Investig. Cientificas Secuencia de acido nucleico que comprende la señal de encapsidacion del rna de un coronavirus del grupo 1 y sus aplicaciones.
ES2208051B1 (es) * 2002-01-24 2005-08-16 Consejo Sup. Investig. Cientificas Secuencia de acido nucleico que comprende la señal de encapsidacion del rna de un coronavirus del grupo 1 y sus aplicaciones.

Also Published As

Publication number Publication date
CA2248978A1 (en) 1997-09-18
US7041300B1 (en) 2006-05-09
WO1997034008A1 (es) 1997-09-18
EP1008652A1 (en) 2000-06-14
KR100360327B1 (ko) 2003-03-28
EP1741789A1 (en) 2007-01-10
HUP0000356A2 (hu) 2000-06-28
US20040052775A1 (en) 2004-03-18
CN1318596C (zh) 2007-05-30
CN1218513A (zh) 1999-06-02
BR9708061A (pt) 2000-01-04
HUP0000356A3 (en) 2001-09-28
AU1927797A (en) 1997-10-01
KR19990087724A (ko) 1999-12-27
RU2199584C2 (ru) 2003-02-27
AU729044B2 (en) 2001-01-25
ES2109189B1 (es) 1998-05-16
PL328791A1 (en) 1999-02-15
PL188546B1 (pl) 2005-02-28
JP3769300B2 (ja) 2006-04-19
JP2000513565A (ja) 2000-10-17
US20070048862A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
ES2109189B1 (es) Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
KR890701757A (ko) 재조합 아비폭스 바이러스
ATE144552T1 (de) Rekombinantes geflügelpockenvirus
ES2141081T3 (es) Nuevo aislado de hcv j-1.
KR880700070A (ko) 비루스 왁찐
ES2138784T3 (es) Antigenos sinteticos para la deteccion de anticuerpos contra el virus de la hepatitis c.
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
Jackson et al. Effect of lymphatic and splenic pump techniques on the antibody response to hepatitis B vaccine: a pilot study
EA200401405A1 (ru) Модифицированный осповакцинный вирус анкара для вакцинации новорожденных
FI910497A0 (fi) Nytt virus vid infektioes bursalsjukdom.
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
NO933261L (no) Blanding til forsterkning av immunforsvaret
CO4520254A1 (es) Vacunas contra tumores y procedimiento para su produccion
Charley et al. Porcine innate and adaptative immune responses to influenza and coronavirus infections
ATE233821T1 (de) Poxvirusvektoren und deren anwendung als impstoff gegen katzenansteckende peritonitis- viruskrankheit
AR004464A1 (es) Un metodo para producir una proteina de capside de papilomavirus
ATE517184T1 (de) Hcv ns3/4a kodierende nukleinsäure
SE9202968D0 (sv) New peptides, diagnostic antigens, use thereof, vaccines and medicaments
Schelp et al. Identification of cell membrane proteins linked to susceptibility to bovine viral diarrhoea virus infection
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
DE68923286D1 (de) Impfstoffe und testsätze für haemophilus influenzae.
Heuschele et al. Local Immunity and Persistence of Virus in the Tracheas of Chickens following Infection with Newcastle Disease Virus. II Immunofluorescent and Histopathologic Studies
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
DE68926274D1 (de) Rekombinante HBsAg Hybridpartikel, die morphologische Eigenschaften von HBsAg-Antigen haben und eine immunogene Sequenz enthalten, die neutralisierende Antikörper gegen HIV induziert oder die von diesen Antikörpern erkannt ist, Nukleotide Sequenzen, die diese Partikel codieren und sie enthaltende Impfstoffe

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19980101

Kind code of ref document: A1

Effective date: 19980101

FD1A Patent lapsed

Effective date: 20080315